Interim report for Diamyd® directly into the lymph node for patients with LADA

An initial interim report from the open-label investigator-initiated clinical trial GADinLADA, in which the diabetes vaccine Diamyd[®] is administered directly into the lymph node in 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults), shows that treatment after five months is safe and tolerable. Preliminary analyses indicate that the immunological response to the treatment is similar to what has been observed in individuals with type 1 diabetes treated with Diamyd[®].“It is of course important that we can state that the